Lead Product(s) : BP2202
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
BrightPath, Cellistic Collaborate on BCMA CAR-iNKT Cell Phase 1 Trial
Details : The collaboration aims to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials.
Product Name : BP2202
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2024
Lead Product(s) : BP2202
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $56.0 million
Deal Type : Series A Financing
EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics
Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : EQT Life Sciences
Deal Size : $56.0 million
Deal Type : Series A Financing
Lead Product(s) : Bisantrene DiHCl
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220
Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Product Name : RC220
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 07, 2023
Lead Product(s) : Bisantrene DiHCl
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : CAMYO-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CAMYO-01 is a novel off-the-shelf cancer vaccine, which is incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.
Product Name : CAMYO-01
Product Type : Vaccine
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : CAMYO-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Fortress Investment Group
Deal Size : $10.5 million
Deal Type : Private Placement
Details : The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA techn...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Fortress Investment Group
Deal Size : $10.5 million
Deal Type : Private Placement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Details : The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances
Details : The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 31, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable